[96a5a0]: / output / chiaCancer / identified / NCT00094861_identified.json

Download this file

907 lines (907 with data), 39.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
{
"info": {
"nct_id": "NCT00094861",
"official_title": "A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",
"inclusion_criteria": "* Patients with a histologically or cytologically proven diagnosis of NSCLC\n* Unresectable (locally advanced) stage IIIa or IIIb disease\n* Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus\n* Life expectancy greater than or equal to 6 months\n* Estimated weight loss less than or equal to 10% in the 3 months before study randomization\n* Measurable disease\n* 18 years of age or older\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2\n* Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization\n* Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization\n* Platelet count greater than or equal to 100 x 10^9/L\n* Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN)\n* Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min)\n* Females of childbearing potential: negative serum or urine pregnancy test\n* Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.\n* Patients with reproductive capability must agree to practice adequate contraception methods.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Metastatic disease (M1)/stage 4 NSCLC\n* Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.\n* Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course\n* Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)\n* Prior chemotherapy, radiotherapy, or surgery for NSCLC\n* Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized.\n* Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease [GERD], dyspepsia, etc)\n* History of pancreatitis\n* Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment\n* Previous treatment on this study or with a fibroblast growth factor\n* Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)\n* Pregnant or breastfeeding women\n* Known sensitivity to E. coli derived products\n* Compromised ability of the patient to give written informed consent and/or to comply with study procedures\n* Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable\n* Unwilling or unable to complete the patient reported outcome (PRO) questionnaires\n* Psychological, social, familial, or geographical reasons that would prevent regular follow-up",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients with a histologically or cytologically proven diagnosis of NSCLC",
"criterions": [
{
"exact_snippets": [
"histologically or cytologically proven diagnosis of NSCLC"
],
"criterion": "NSCLC diagnosis",
"requirement_type": "method of confirmation",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"line": "* Unresectable (locally advanced) stage IIIa or IIIb disease",
"criterions": [
{
"exact_snippets": [
"Unresectable"
],
"criterion": "disease",
"requirement_type": "resectability",
"expected_value": false
},
{
"exact_snippets": [
"locally advanced"
],
"criterion": "disease",
"requirement_type": "stage",
"expected_value": "locally advanced"
},
{
"exact_snippets": [
"stage IIIa or IIIb"
],
"criterion": "disease",
"requirement_type": "stage",
"expected_value": [
"IIIa",
"IIIb"
]
}
]
},
{
"line": "* Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus",
"criterions": [
{
"exact_snippets": [
"Initial radiotherapy field of treatment"
],
"criterion": "radiotherapy field of treatment",
"requirement_type": "initial",
"expected_value": true
},
{
"exact_snippets": [
"encompass greater than or equal to 30% of the esophagus"
],
"criterion": "esophagus",
"requirement_type": "coverage",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 30
}
]
}
}
]
},
{
"line": "* Life expectancy greater than or equal to 6 months",
"criterions": [
{
"exact_snippets": [
"Life expectancy greater than or equal to 6 months"
],
"criterion": "life expectancy",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 6
}
]
}
}
]
},
{
"line": "* Estimated weight loss less than or equal to 10% in the 3 months before study randomization",
"criterions": [
{
"exact_snippets": [
"Estimated weight loss",
"less than or equal to 10%"
],
"criterion": "weight loss",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 10
}
]
}
},
{
"exact_snippets": [
"in the 3 months before study randomization"
],
"criterion": "time frame before study randomization",
"requirement_type": "duration",
"expected_value": "3 months"
}
]
},
{
"line": "* Measurable disease",
"criterions": [
{
"exact_snippets": [
"Measurable disease"
],
"criterion": "disease",
"requirement_type": "measurability",
"expected_value": true
}
]
},
{
"line": "* 18 years of age or older",
"criterions": [
{
"exact_snippets": [
"18 years of age or older"
],
"criterion": "age",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18
}
]
}
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2",
"criterions": [
{
"exact_snippets": [
"Eastern Cooperative Oncology Group (ECOG) performance status"
],
"criterion": "ECOG performance status",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0
},
{
"operator": "<=",
"value": 2
}
]
}
}
]
},
{
"line": "* Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization",
"criterions": [
{
"exact_snippets": [
"Hemoglobin (hgb) greater than or equal to 10 g/dL"
],
"criterion": "hemoglobin",
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 10
}
]
}
},
{
"exact_snippets": [
"without transfusional support"
],
"criterion": "transfusional support",
"requirement_type": "use",
"expected_value": false
},
{
"exact_snippets": [
"without",
"growth factor use"
],
"criterion": "growth factor",
"requirement_type": "use",
"expected_value": false
},
{
"exact_snippets": [
"in the 4 weeks before study randomization"
],
"criterion": "time before study randomization",
"requirement_type": "duration",
"expected_value": "4 weeks"
}
]
},
{
"line": "* Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization",
"criterions": [
{
"exact_snippets": [
"Absolute neutrophil count (ANC)",
"greater than or equal to 1.5 x 10^9/L"
],
"criterion": "absolute neutrophil count",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1500000000.0
}
]
}
},
{
"exact_snippets": [
"without growth factor use",
"in the 2 weeks before study randomization"
],
"criterion": "growth factor use",
"requirement_type": "absence",
"expected_value": true
}
]
},
{
"line": "* Platelet count greater than or equal to 100 x 10^9/L",
"criterions": [
{
"exact_snippets": [
"Platelet count greater than or equal to 100 x 10^9/L"
],
"criterion": "platelet count",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 100
}
]
}
}
]
},
{
"line": "* Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": [
"Serum bilirubin",
"less than or equal to 1.5 x institutional upper limit of normal (ULN)"
],
"criterion": "serum bilirubin",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 1.5
}
]
}
}
]
},
{
"line": "* Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min)",
"criterions": [
{
"exact_snippets": [
"Serum creatinine less than or equal to 2.0 mg/dL"
],
"criterion": "serum creatinine",
"requirement_type": "quantity",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2.0
}
]
}
},
{
"exact_snippets": [
"serum creatinine greater than or equal to 1.4",
"less than or equal to 2.0 mg/dL"
],
"criterion": "serum creatinine",
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1.4
},
{
"operator": "<=",
"value": 2.0
}
]
}
},
{
"exact_snippets": [
"24-hour urinary creatinine clearance greater than or equal to 50 mL/min"
],
"criterion": "24-hour urinary creatinine clearance",
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 50
}
}
]
},
{
"line": "* Females of childbearing potential: negative serum or urine pregnancy test",
"criterions": [
{
"exact_snippets": [
"Females of childbearing potential"
],
"criterion": "childbearing potential",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"negative serum or urine pregnancy test"
],
"criterion": "pregnancy test",
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"line": "* Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.",
"criterions": [
{
"exact_snippets": [
"Patient must give written informed consent"
],
"criterion": "informed consent",
"requirement_type": "provision",
"expected_value": true
}
]
},
{
"line": "* Patients with reproductive capability must agree to practice adequate contraception methods.",
"criterions": [
{
"exact_snippets": [
"Patients with reproductive capability"
],
"criterion": "reproductive capability",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"must agree to practice adequate contraception methods"
],
"criterion": "contraception methods",
"requirement_type": "agreement to practice",
"expected_value": true
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": [
"Healthy volunteers allowed"
],
"criterion": "volunteer health status",
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": [
"minimum age of 18 Years"
],
"criterion": "age",
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18
}
}
]
}
],
"exclusion_lines": [
{
"line": "* Metastatic disease (M1)/stage 4 NSCLC",
"criterions": [
{
"exact_snippets": [
"Metastatic disease"
],
"criterion": "metastatic disease",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"stage 4 NSCLC"
],
"criterion": "NSCLC",
"requirement_type": "stage",
"expected_value": "4"
}
]
},
{
"line": "* Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging (positron emission tomography [PET], computed tomography [CT] scan or ultrasound). If an effusion greater than 100 ml is documented by cytology to be free from malignancy and the investigator feels the patient is capable of receiving chemo/radiotherapy for their primary disease/ NSCLC, the investigator should discuss the patient with the study physician at Amgen. Effusions smaller than 100 ml would be acceptable, unless the investigator suspects that the effusion is malignant, in which case the effusions should be evaluated by cytology. Sponsor approval must be obtained before patient is randomized.",
"criterions": [
{
"exact_snippets": [
"Pleural or pericardial effusion greater than 100 ml in volume"
],
"criterion": "pleural or pericardial effusion",
"requirement_type": "volume",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 100
}
]
}
},
{
"exact_snippets": [
"effusion greater than 100 ml is documented by cytology to be free from malignancy"
],
"criterion": "effusion",
"requirement_type": "malignancy",
"expected_value": false
},
{
"exact_snippets": [
"Effusions smaller than 100 ml would be acceptable"
],
"criterion": "effusion",
"requirement_type": "volume",
"expected_value": {
"comparisons": [
{
"operator": "<",
"value": 100
}
]
}
},
{
"exact_snippets": [
"unless the investigator suspects that the effusion is malignant"
],
"criterion": "effusion",
"requirement_type": "malignancy",
"expected_value": true
}
]
},
{
"line": "* Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course",
"criterions": [
{
"exact_snippets": [
"remove the tumor surgically"
],
"criterion": "tumor",
"requirement_type": "removal plan",
"expected_value": true
},
{
"exact_snippets": [
"before completing the protocol chemo/radiotherapy course"
],
"criterion": "protocol chemo/radiotherapy course",
"requirement_type": "completion",
"expected_value": false
}
]
},
{
"line": "* Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)",
"criterions": [
{
"exact_snippets": [
"Shielding of any part of the esophagus during radiotherapy"
],
"criterion": "esophagus",
"requirement_type": "shielding during radiotherapy",
"expected_value": true
},
{
"exact_snippets": [
"posterior spinal cord shielding"
],
"criterion": "spinal cord",
"requirement_type": "posterior shielding",
"expected_value": true
}
]
},
{
"line": "* Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer. Note: Patients with prior surgically-cured malignancies [eg, stage I breast cancer or prostate cancer, in-situ carcinoma of the cervix, etc] are not excluded; however, sponsor approval must be obtained before patient is randomized.",
"criterions": [
{
"exact_snippets": [
"Prior invasive malignancy during the past 3 years"
],
"criterion": "prior invasive malignancy",
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3
}
]
}
},
{
"exact_snippets": [
"non-melanomatous skin cancer"
],
"criterion": "non-melanomatous skin cancer",
"requirement_type": "exclusion",
"expected_value": true
},
{
"exact_snippets": [
"prior surgically-cured malignancies"
],
"criterion": "prior surgically-cured malignancies",
"requirement_type": "exclusion",
"expected_value": true
},
{
"exact_snippets": [
"sponsor approval must be obtained"
],
"criterion": "sponsor approval",
"requirement_type": "requirement",
"expected_value": true
}
]
},
{
"line": "* Presence or history of dysphagia or conditions predisposing to dysphagia (eg, uncontrolled gastroesophageal reflux disease [GERD], dyspepsia, etc)",
"criterions": [
{
"exact_snippets": [
"Presence or history of dysphagia"
],
"criterion": "dysphagia",
"requirement_type": "presence or history",
"expected_value": true
},
{
"exact_snippets": [
"conditions predisposing to dysphagia"
],
"criterion": "conditions predisposing to dysphagia",
"requirement_type": "presence",
"expected_value": true
},
{
"exact_snippets": [
"uncontrolled gastroesophageal reflux disease [GERD]"
],
"criterion": "gastroesophageal reflux disease",
"requirement_type": "control",
"expected_value": false
},
{
"exact_snippets": [
"dyspepsia"
],
"criterion": "dyspepsia",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* History of pancreatitis",
"criterions": [
{
"exact_snippets": [
"History of pancreatitis"
],
"criterion": "pancreatitis",
"requirement_type": "history",
"expected_value": true
}
]
},
{
"line": "* Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment",
"criterions": [
{
"exact_snippets": [
"Four weeks or less since completion of treatment using an investigational product/device in another clinical study"
],
"criterion": "time since completion of treatment in another clinical study",
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4
}
]
}
},
{
"exact_snippets": [
"presence of any unresolved toxicity from previous treatment"
],
"criterion": "unresolved toxicity from previous treatment",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* Pregnant or breastfeeding women",
"criterions": [
{
"exact_snippets": [
"Pregnant"
],
"criterion": "pregnancy",
"requirement_type": "status",
"expected_value": true
},
{
"exact_snippets": [
"breastfeeding"
],
"criterion": "breastfeeding",
"requirement_type": "status",
"expected_value": true
}
]
},
{
"line": "* Known sensitivity to E. coli derived products",
"criterions": [
{
"exact_snippets": [
"Known sensitivity to E. coli derived products"
],
"criterion": "sensitivity to E. coli derived products",
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"line": "* Compromised ability of the patient to give written informed consent and/or to comply with study procedures",
"criterions": [
{
"exact_snippets": [
"Compromised ability of the patient to give written informed consent"
],
"criterion": "ability to give written informed consent",
"requirement_type": "compromised",
"expected_value": true
},
{
"exact_snippets": [
"comply with study procedures"
],
"criterion": "ability to comply with study procedures",
"requirement_type": "compromised",
"expected_value": true
}
]
},
{
"line": "* Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable",
"criterions": [
{
"exact_snippets": [
"Refusal to sign an informed consent form"
],
"criterion": "informed consent form",
"requirement_type": "signature",
"expected_value": false
},
{
"exact_snippets": [
"sign the hospital information release form"
],
"criterion": "hospital information release form",
"requirement_type": "signature",
"expected_value": true
}
]
},
{
"line": "* Unwilling or unable to complete the patient reported outcome (PRO) questionnaires",
"criterions": [
{
"exact_snippets": [
"Unwilling",
"to complete the patient reported outcome (PRO) questionnaires"
],
"criterion": "completion of PRO questionnaires",
"requirement_type": "willingness",
"expected_value": true
},
{
"exact_snippets": [
"unable",
"to complete the patient reported outcome (PRO) questionnaires"
],
"criterion": "completion of PRO questionnaires",
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"line": "* Psychological, social, familial, or geographical reasons that would prevent regular follow-up",
"criterions": [
{
"exact_snippets": [
"Psychological",
"reasons that would prevent regular follow-up"
],
"criterion": "psychological reasons",
"requirement_type": "impact on follow-up",
"expected_value": true
},
{
"exact_snippets": [
"social",
"reasons that would prevent regular follow-up"
],
"criterion": "social reasons",
"requirement_type": "impact on follow-up",
"expected_value": true
},
{
"exact_snippets": [
"familial",
"reasons that would prevent regular follow-up"
],
"criterion": "familial reasons",
"requirement_type": "impact on follow-up",
"expected_value": true
},
{
"exact_snippets": [
"geographical",
"reasons that would prevent regular follow-up"
],
"criterion": "geographical reasons",
"requirement_type": "impact on follow-up",
"expected_value": true
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Prior chemotherapy, radiotherapy, or surgery for NSCLC",
"criterions": [
{
"exact_snippets": [
"Prior chemotherapy"
],
"criterion": "chemotherapy",
"requirement_type": "prior treatment",
"expected_value": true
},
{
"exact_snippets": [
"Prior radiotherapy"
],
"criterion": "radiotherapy",
"requirement_type": "prior treatment",
"expected_value": true
},
{
"exact_snippets": [
"Prior surgery for NSCLC"
],
"criterion": "surgery for NSCLC",
"requirement_type": "prior treatment",
"expected_value": true
}
]
},
{
"line": "* Previous treatment on this study or with a fibroblast growth factor",
"criterions": [
{
"exact_snippets": [
"Previous treatment on this study"
],
"criterion": "previous treatment",
"requirement_type": "participation",
"expected_value": true
},
{
"exact_snippets": [
"previous treatment",
"with a fibroblast growth factor"
],
"criterion": "fibroblast growth factor treatment",
"requirement_type": "history",
"expected_value": true
}
]
},
{
"line": "* Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)",
"criterions": [
{
"exact_snippets": [
"sero-positive for human immunodeficiency virus (HIV)"
],
"criterion": "human immunodeficiency virus (HIV)",
"requirement_type": "sero-positivity",
"expected_value": true
},
{
"exact_snippets": [
"sero-positive for hepatitis C virus (HCV)"
],
"criterion": "hepatitis C virus (HCV)",
"requirement_type": "sero-positivity",
"expected_value": true
},
{
"exact_snippets": [
"sero-positive for hepatitis B virus (HBV)"
],
"criterion": "hepatitis B virus (HBV)",
"requirement_type": "sero-positivity",
"expected_value": true
}
]
}
],
"failed_miscellaneous": []
}